Adickes: Stem cell therapy
♫ Tuesday, October 4th, 2011Dr. Mark Adickes discusses the use of stem cells in treating injured athletes.
Continue reading here:
Adickes: Stem cell therapy
Archive for the ‘Stem Cell Therapy’ Category
Benefits of STEM CELL THERAPY – Adipose Tissue
♫ Tuesday, October 4th, 2011Follow this link:
Benefits of STEM CELL THERAPY - Adipose Tissue
Representative Brian Bilbray Meets with International Stem Cell Executives to Discuss Research Funding
♫ Sunday, October 2nd, 2011International Stem Cell Corporation (OTCBB: ISCO) today announced that Representative Brian Bilbray recently met with Company executives, including Chairman Kenneth Aldrich, President and Chief Executive Officer Andrey Semechkin, and Senior Vice President Kurt May, to discuss key federal government issues relating to stem cell research. Rep. Bilbray represents California's 50th congressional district, which includes portions of San Diego's North County.
Following the meeting, Rep. Bilbray stated, "I have tremendous respect for the innovative healthcare companies in my district, such as International Stem Cell, that are at the forefront of developing important new treatments and therapies. I'm committed to helping remove unnecessary regulations and barriers that may inhibit the research of new life science technologies, and I greatly appreciate the efforts of ISCO's management team to clarify many of the issues surrounding their work."
Said Dr. Semechkin, "We are very pleased to have the opportunity to meet with Congressman Bilbray and explain the importance of our parthenogenesis technology and how it differs from human embryonic stem cell development, particularly from an ethical standpoint. We look forward to continued discussions with Congressman Bilbray and his colleagues regarding the Dickey-Wicker Amendment. We believe that with increased understanding of our technology the National Institutes of Health (NIH) will support parthenogenesis research and development."
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
Forward-looking Statements
Statements pertaining to anticipated developments, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.
International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
760-940-6383
or
Lippert/Heilshorn & Associates
Don Markley
310-691-7100
Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss
Representative Brian Bilbray Meets with International Stem Cell Executives to Discuss Research Funding
♫ Sunday, October 2nd, 2011International Stem Cell Corporation (OTCBB: ISCO) today announced that Representative Brian Bilbray recently met with Company executives, including Chairman Kenneth Aldrich, President and Chief Executive Officer Andrey Semechkin, and Senior Vice President Kurt May, to discuss key federal government issues relating to stem cell research. Rep. Bilbray represents California's 50th congressional district, which includes portions of San Diego's North County.
Following the meeting, Rep. Bilbray stated, "I have tremendous respect for the innovative healthcare companies in my district, such as International Stem Cell, that are at the forefront of developing important new treatments and therapies. I'm committed to helping remove unnecessary regulations and barriers that may inhibit the research of new life science technologies, and I greatly appreciate the efforts of ISCO's management team to clarify many of the issues surrounding their work."
Said Dr. Semechkin, "We are very pleased to have the opportunity to meet with Congressman Bilbray and explain the importance of our parthenogenesis technology and how it differs from human embryonic stem cell development, particularly from an ethical standpoint. We look forward to continued discussions with Congressman Bilbray and his colleagues regarding the Dickey-Wicker Amendment. We believe that with increased understanding of our technology the National Institutes of Health (NIH) will support parthenogenesis research and development."
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
Forward-looking Statements
Statements pertaining to anticipated developments, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.
International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
760-940-6383
or
Lippert/Heilshorn & Associates
Don Markley
310-691-7100
Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss
Stem Cell Treatment in New Jersey- Colon’s story (Dr Damon Noto)
♫ Sunday, October 2nd, 2011Doctor Damon Noto, with offices in NYC and New Jersey, was a featured guest on Channel 12 News to talk about Stem Cell Treatment performed on Yankee's pitcher Bartolo Colon. Doctor Noto also discussed the latest cutting edge therapy that heals the body using your own stem cells. Doctor Damon Noto is among a handful of doctors in the tristate area performing Regenerative Stem Cell Therapy
Go here to see the original:
Stem Cell Treatment in New Jersey- Colon's story (Dr Damon Noto)
Stem Cell Therapy for Pets – By A Touch of Love® Inc. Part 1 of 5
♫ Saturday, October 1st, 2011Pawzzzz for the NEWS! - Produced by A Touch of Love® http://WWW.ATOUCHOFLOVE.CA Education on Stem Cell Therapy for Pets. Part 1 of 5 part series. Understand the benefits of stem cell therapy and our companion animals.
Here is the original post:
Stem Cell Therapy for Pets - By A Touch of Love® Inc. Part 1 of 5
Post Stem Cell Therapy Testimony of Cerebral Palsy
♫ Wednesday, September 28th, 2011Stem cell therapy done at neurogen brain and spine institute pvt ltd.
See the rest here:
Post Stem Cell Therapy Testimony of Cerebral Palsy
What could stem cell therapy do for Peyton?
♫ Monday, September 26th, 2011Indianapolis Colts quarterback Peyton Manning reportedly went to Europe for adult stem cell therapy for his ailing neck, according to published and broadcast reports. But what would such a procedure accomplish, and why would he have to travel to Europe for it?
Read more:
What could stem cell therapy do for Peyton?
Lifeline Skin Care Video: Care For Your Skin with Lifeline Skin Care
♫ Sunday, September 25th, 2011Stem Cell Skin Care
Born Different.
Lifeline Skin Care® (Lifeline) is a wholly owned subsidiary of International Stem Cell Corporation (OTCBB:ISCO), a publicly traded biotechnology company which has developed a powerful and ethical new stem cell technology called “parthenogenesis”. ISCO created Lifeline Skin Care® to further develop its discoveries that extracts from human parthenogenetic stem cells had beneficial effects on human skin cells.
International Stem Cell is focused on advancing its human parthenogenetic stem cell technology towards finding treatments for blinding diseases of the eye, liver disease, diseases of the nervous system and diabetes.
Our goal at Lifeline Skin Care® is to help individuals improve the look and feel of their skin by combining the latest discoveries in the fields of stem cell biology, nanotechnology and skin cream formulation technology to create the highest quality, scientifically tested and most effective skin care products.
Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss
Lifeline Skin Care Video: Care For Your Skin with Lifeline Skin Care
♫ Sunday, September 25th, 2011Stem Cell Skin Care
Born Different.
Lifeline Skin Care® (Lifeline) is a wholly owned subsidiary of International Stem Cell Corporation (OTCBB:ISCO), a publicly traded biotechnology company which has developed a powerful and ethical new stem cell technology called “parthenogenesis”. ISCO created Lifeline Skin Care® to further develop its discoveries that extracts from human parthenogenetic stem cells had beneficial effects on human skin cells.
International Stem Cell is focused on advancing its human parthenogenetic stem cell technology towards finding treatments for blinding diseases of the eye, liver disease, diseases of the nervous system and diabetes.
Our goal at Lifeline Skin Care® is to help individuals improve the look and feel of their skin by combining the latest discoveries in the fields of stem cell biology, nanotechnology and skin cream formulation technology to create the highest quality, scientifically tested and most effective skin care products.
Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss
Cancer Stem Cell Chronicle
♫ Sunday, September 18th, 2011About 3 months ago, as an experiment, I launched the Cancer Stem Cell Chronicle, an online daily newspaper that's based on excerpts from 3 streams of content: 1) Twitter content tagged #cancerSC, 2) Twitter content that includes the keywords "cancer stem", and, 3) content derived from a PubMed RSS feed for the search term "cancer stem".
The experiment looks promising. The CSC Chronicle is beginning to provide a convenient way to monitor recent research news about cancer stem cells. Archives are available. The section headings in the CSC Chronicle aren't very meaningful, and should be ignored.
The CSC Chronicle is hosted by Paper.li.
Source:
http://cancerstemcellnews.blogspot.com/feeds/posts/default?alt=rss
Cancer Stem Cell Chronicle
♫ Sunday, September 18th, 2011About 3 months ago, as an experiment, I launched the Cancer Stem Cell Chronicle, an online daily newspaper that's based on excerpts from 3 streams of content: 1) Twitter content tagged #cancerSC, 2) Twitter content that includes the keywords "cancer stem", and, 3) content derived from a PubMed RSS feed for the search term "cancer stem".
The experiment looks promising. The CSC Chronicle is beginning to provide a convenient way to monitor recent research news about cancer stem cells. Archives are available. The section headings in the CSC Chronicle aren't very meaningful, and should be ignored.
The CSC Chronicle is hosted by Paper.li.
Source:
http://cancerstemcellnews.blogspot.com/feeds/posts/default?alt=rss
Repair Your Joint Injuries With Stem Cell Therapy | Los Angeles | Beverly Hills | Hollywood
♫ Friday, September 16th, 2011metromd.net Stem Cell Therapy for Repairing Joint Injuries | Stem Cell Therapy is effective in many orthopedic applications. Restore function and relieve pain from torn ligaments, tendons and damaged cartilage. By Dr
More here:
Repair Your Joint Injuries With Stem Cell Therapy | Los Angeles | Beverly Hills | Hollywood
International Stem Cell to Present at the Rodman & Renshaw Annual Global Investment Conference on September 12
♫ Sunday, September 11th, 2011
International Stem Cell Corporation (OTCBB: ISCO) announced today that Kenneth Aldrich, Chairman, is scheduled to present at the Rodman & Renshaw Annual Global Investment Conference on Monday, September 12, 2011 at 11:40 a.m. Eastern (8:40 a.m. Pacific). The conference takes place at the Waldorf Astoria Hotel in New York City.
A webcast of the International Stem Cell Corporation presentation can be viewed live at http://www.wsw.com/webcast/rrshq20/isco. The presentation will be archived and available at the same link for 90 days. After the conference, a link to the presentation will also be posted to the ISCO website, http://www.intlstemcell.com.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
International Stem Cell Corporation
Kenneth C Aldrich, Chairman
760-940-6383
or
Lippert/Heilshorn & Associates
Don Markley
310-691-7100
Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss
Video: The Promising Cells Presented by International Stem Cell Corporation
♫ Sunday, September 11th, 2011Ken Aldrich of International Stem Cell Corporation (ISCO.OB) on the latest research involving stem cell technology utilizing unfertilized eggs, as a basis for cell generation with a goal toward organ transplants which are immune to rejection by the body...as well as other applications. Mr. Aldrich also discusses neurological applications focusing on reversing Parkinson's disease.
This corporate video was produced by Big Sky Productions Inc. (BGSI.OB).
Executive Producer: Ellis Martin
Producer and Creative Director, Narrator, Editor: Bob Lange
contact: bigskymedia@yahoo.com
Video Link - http://www.youtube.com/watch?v=CcXPMHqENys
Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss
International Stem Cell to Present at the Rodman & Renshaw Annual Global Investment Conference on September 12
♫ Sunday, September 11th, 2011
International Stem Cell Corporation (OTCBB: ISCO) announced today that Kenneth Aldrich, Chairman, is scheduled to present at the Rodman & Renshaw Annual Global Investment Conference on Monday, September 12, 2011 at 11:40 a.m. Eastern (8:40 a.m. Pacific). The conference takes place at the Waldorf Astoria Hotel in New York City.
A webcast of the International Stem Cell Corporation presentation can be viewed live at http://www.wsw.com/webcast/rrshq20/isco. The presentation will be archived and available at the same link for 90 days. After the conference, a link to the presentation will also be posted to the ISCO website, http://www.intlstemcell.com.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
International Stem Cell Corporation
Kenneth C Aldrich, Chairman
760-940-6383
or
Lippert/Heilshorn & Associates
Don Markley
310-691-7100
Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss
Video: The Promising Cells Presented by International Stem Cell Corporation
♫ Sunday, September 11th, 2011Ken Aldrich of International Stem Cell Corporation (ISCO.OB) on the latest research involving stem cell technology utilizing unfertilized eggs, as a basis for cell generation with a goal toward organ transplants which are immune to rejection by the body...as well as other applications. Mr. Aldrich also discusses neurological applications focusing on reversing Parkinson's disease.
This corporate video was produced by Big Sky Productions Inc. (BGSI.OB).
Executive Producer: Ellis Martin
Producer and Creative Director, Narrator, Editor: Bob Lange
contact: bigskymedia@yahoo.com
Video Link - http://www.youtube.com/watch?v=CcXPMHqENys
Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss
Duffy Update, Post Stem Cell Therapy
♫ Monday, September 5th, 2011Aarff.com does a followup on Duffy, a 10 year old Lab who underwent stem cell therapy two months ago in June 2011
Go here to see the original:
Duffy Update, Post Stem Cell Therapy
Spinal Cord Injury – Stem Cell Therapy
♫ Saturday, September 3rd, 2011Franklin is a patient with spinal cord injury.
Continued here:
Spinal Cord Injury - Stem Cell Therapy
International Stem Cell Corporation presents "The Promising Cells" Video
♫ Sunday, August 28th, 2011In this video presentation, see and hear an overview of International Stem Cell Corporation (ISCO.OB). ISCO has developed a process to derive stem cells similar to Embryonic Stem Cells without the need for fertilized embryos and with minimal exposure to non-human cells. These factors provide ISC a unique leadership role in the field of regenerative cell therapy. You'll hear directly from Executive Chairman, Kenneth Aldrich. Lifeline Cell Technology and Skin Care Products, revenue generating units of ISCO are also reviewed.
This presentation was produced by Big Sky Productions, INC (BGSI.OB), Co-Executive Producers Ellis Martin and Bob Lange.
contact: bigskymedia@yahoo.com
Unfortunately, this content is currently being updated and will be posted again soon.
Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss